Literature DB >> 24493718

Reply to M.C. Chamberlain.

James L Rubenstein1, Bruce D Cheson, Sin-Ho Jung, Lawrence D Kaplan.   

Abstract

Mesh：

Year:  2014        PMID： 24493718      PMCID： PMC3940542          DOI： 10.1200/JCO.2013.53.8942

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  32 in total

1.  Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

Authors:  V Boehme; S Zeynalova; M Kloess; M Loeffler; U Kaiser; M Pfreundschuh; N Schmitz
Journal:  Ann Oncol       Date:  2006-10-03       Impact factor: 32.976

2.  Measurements of blood-brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma.

Authors:  R J Ott; M Brada; M A Flower; J W Babich; S R Cherry; B J Deehan
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

3.  Gene expression and angiotropism in primary CNS lymphoma.

Authors:  James L Rubenstein; Jane Fridlyand; Arthur Shen; Ken Aldape; David Ginzinger; Tracy Batchelor; Patrick Treseler; Mitchel Berger; Michael McDermott; Michael Prados; Jon Karch; Craig Okada; William Hyun; Seema Parikh; Chris Haqq; Marc Shuman
Journal:  Blood       Date:  2006-01-17       Impact factor: 22.113

4.  High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?

Authors:  M J Glantz; B F Cole; L Recht; W Akerley; P Mills; S Saris; F Hochberg; P Calabresi; M J Egorin
Journal:  J Clin Oncol       Date:  1998-04       Impact factor: 44.544

5.  High incidence of secondary brain tumours after radiotherapy and antimetabolites.

Authors:  M V Relling; J E Rubnitz; G K Rivera; J M Boyett; M L Hancock; C A Felix; L E Kun; A W Walter; W E Evans; C H Pui
Journal:  Lancet       Date:  1999-07-03       Impact factor: 79.321

6.  Extreme sensitivity of adult neurogenesis to low doses of X-irradiation.

Authors:  Shinichiro Mizumatsu; Michelle L Monje; Duncan R Morhardt; Radoslaw Rola; Theo D Palmer; John R Fike
Journal:  Cancer Res       Date:  2003-07-15       Impact factor: 12.701

7.  Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children's Research Hospital.

Authors:  A W Walter; M L Hancock; C H Pui; M M Hudson; J S Ochs; G K Rivera; C B Pratt; J M Boyett; L E Kun
Journal:  J Clin Oncol       Date:  1998-12       Impact factor: 44.544

8.  Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment.

Authors:  James L Rubenstein; Dan Combs; Jay Rosenberg; Arthur Levy; Michael McDermott; Lloyd Damon; Robert Ignoffo; Kenneth Aldape; Arthur Shen; Dana Lee; Antonio Grillo-Lopez; Marc A Shuman
Journal:  Blood       Date:  2002-09-05       Impact factor: 22.113

9.  Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia.

Authors:  M V Relling; H H Mahmoud; C H Pui; J T Sandlund; G K Rivera; R C Ribeiro; W M Crist; W E Evans
Journal:  J Clin Oncol       Date:  1996-02       Impact factor: 44.544

10.  Temozolomide as salvage treatment in primary brain lymphomas.

Authors:  M Reni; F Zaja; W Mason; J Perry; E Mazza; M Spina; R Bordonaro; F Ilariucci; M Faedi; G Corazzelli; P Manno; E Franceschi; A Pace; M Candela; A Abbadessa; C Stelitano; G Latte; A J M Ferreri
Journal:  Br J Cancer       Date:  2007-02-27       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.